-
1
-
-
84906049978
-
-
Available from Last accessed 17 January 2014]
-
Hepatitis C. WHO. 2013.Available from: Http://www.who. int/mediacentre/factsheets/fs164/en/index. html [Last accessed 17 January 2014]
-
(2013)
Hepatitis C. WHO
-
-
-
2
-
-
84894707183
-
Expanded classification of hepatitis C Virus into 7 genotypes and 67 Subtypes: Updated criteria and assignment web resource
-
Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C Virus into 7 genotypes and 67 Subtypes: Updated criteria and assignment web resource. Hepatology 2013;1:318-27
-
(2013)
Hepatology
, vol.1
, pp. 318-327
-
-
Smith, D.B.1
Bukh, J.2
Kuiken, C.3
-
3
-
-
84885799512
-
HCV-related autoimmune disorders in HCV chronic infection
-
Ferrari SM, Fallahi P, Mancusi C, et al. HCV-related autoimmune disorders in HCV chronic infection. Clin Ter 2013;164:e305-12
-
(2013)
Clin ter
-
-
Ferrari, S.M.1
Fallahi, P.2
Mancusi, C.3
-
4
-
-
83855160892
-
Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy
-
Coppola N, Pisaturo M, Guastafierro S, et al. Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy. Dig Liver Dis 2012;44:49-54
-
(2012)
Dig Liver Dis
, vol.44
, pp. 49-54
-
-
Coppola, N.1
Pisaturo, M.2
Guastafierro, S.3
-
5
-
-
84879798869
-
Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C
-
Zampino R CN, Cirillo G, Boemio A, et al. Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C. J Viral Hepat 2013;20:517-23
-
(2013)
J Viral Hepat
, vol.20
, pp. 517-523
-
-
Zampino, R.C.N.1
Cirillo, G.2
Boemio, A.3
-
6
-
-
84888855025
-
Sustained virological response to antiviral treatment in chronic hepatitis C patients may be predictable by HCV-RNA clearance in peripheral blood mononuclear cells
-
Coppola N, De Pascalis S, Pisaturo M, et al. Sustained virological response to antiviral treatment in chronic hepatitis C patients may be predictable by HCV-RNA clearance in peripheral blood mononuclear cells. J Clin Virol 2013;58(4):748-50
-
(2013)
J Clin Virol
, vol.58
, Issue.4
, pp. 748-750
-
-
Coppola, N.1
De Pascalis, S.2
Pisaturo, M.3
-
8
-
-
84887924285
-
Erectile dysfunction in patients with chronic viral hepatitis: A systematic review of the literature
-
Fusco F, DAnzeo G, Rossi A, et al. Erectile dysfunction in patients with chronic viral hepatitis: A systematic review of the literature. Expert Opin Pharmacother 2013;14:2533-44
-
(2013)
Expert Opin Pharmacother
, vol.14
, pp. 2533-2544
-
-
Fusco, F.1
Danzeo, G.2
Rossi, A.3
-
9
-
-
78751621217
-
Evolving epidemiology of hepatitis C virus
-
Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011;17:107-15
-
(2011)
Clin Microbiol Infect
, vol.17
, pp. 107-115
-
-
Lavanchy, D.1
-
10
-
-
0030928695
-
Hepatitis C the clinical spectrum of disease
-
Hoofnagle JH. Hepatitis C: The clinical spectrum of disease. Hepatology 1997;26:15S-20S
-
(1997)
Hepatology
, vol.26
-
-
Hoofnagle, J.H.1
-
11
-
-
84882779407
-
Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C
-
Sagnelli E, Pisaturo M, Stanzione M, et al. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C. Clin Gastroenterol Hepatol 2013;11:1174-80
-
(2013)
Clin Gastroenterol Hepatol
, vol.11
, pp. 1174-1180
-
-
Sagnelli, E.1
Pisaturo, M.2
Stanzione, M.3
-
12
-
-
84893696310
-
Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C
-
Coppola N, Gentile I, Pasquale G, et al. Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C. Ann Hepatol 2014;13:20-6
-
(2014)
Ann Hepatol
, vol.13
, pp. 20-26
-
-
Coppola, N.1
Gentile, I.2
Pasquale, G.3
-
13
-
-
84877647206
-
A simple noninvasive score based on routine parameters can predict liver cirrhosis in patients with chronic Hepatitis C
-
Gentile I, Coppola N, Pasquale G, et al. A simple noninvasive score based on routine parameters can predict liver cirrhosis in patients with chronic Hepatitis C. Hepat Mon 2013;13:e8352
-
(2013)
Hepat Mon
, vol.13
-
-
Gentile, I.1
Coppola, N.2
Pasquale, G.3
-
14
-
-
40749111024
-
Multiple sclerosis and hepatitis C virus infection are associated with single nucleotide polymorphisms in interferon pathway genes
-
Fortunato G, Calcagno G, Bresciamorra V, et al. Multiple sclerosis and hepatitis C virus infection are associated with single nucleotide polymorphisms in interferon pathway genes. J Interferon Cytokine Res 2008;28:141-52
-
(2008)
J Interferon Cytokine Res
, vol.28
, pp. 141-152
-
-
Fortunato, G.1
Calcagno, G.2
Bresciamorra, V.3
-
15
-
-
0034859335
-
Multivariate discriminant function based on six biochemical markers in blood can predict the cirrhotic evolution of chronic hepatitis
-
Fortunato G, Castaldo G, Oriani G, et al. Multivariate discriminant function based on six biochemical markers in blood can predict the cirrhotic evolution of chronic hepatitis. Clin Chem 2001;47:1696-700
-
(2001)
Clin Chem
, vol.47
, pp. 1696-1700
-
-
Fortunato, G.1
Castaldo, G.2
Oriani, G.3
-
16
-
-
84892722703
-
Human platelet antigen-3 genotype predicts platelet count in patients with HCV infection
-
Gentile I, Meola M, Buonomo AR, et al. Human platelet antigen-3 genotype predicts platelet count in patients with HCV infection. In Vivo 2013;27:773-7
-
(2013)
Vivo
, vol.27
, pp. 773-777
-
-
Gentile, I.1
Meola, M.2
Buonomo, A.R.3
-
17
-
-
0035206140
-
Does HIV infection favor the sexual transmission of hepatitis C?
-
Filippini P, Coppola N, Scolastico C, et al Does HIV infection favor the sexual transmission of hepatitis C? Sex Transm Dis 2001;28:725-9
-
(2001)
Sex Transm Dis
, vol.28
, pp. 725-729
-
-
Filippini, P.1
Coppola, N.2
Scolastico, C.3
-
18
-
-
2942626249
-
Influence of chronic coinfection with hepatitis B and C virus on liver histology
-
Sagnelli E, Pasquale G, Coppola N, et al. Influence of chronic coinfection with hepatitis B and C virus on liver histology. Infection 2004;32:144-8
-
(2004)
Infection
, vol.32
, pp. 144-148
-
-
Sagnelli, E.1
Pasquale, G.2
Coppola, N.3
-
19
-
-
84897421294
-
Is it possible to predict HCVrelated liver cirrhosis non-invasively through routine laboratory parameters?
-
Gentile I, Buonomo AR, Zappulo E, et al Is it possible to predict HCVrelated liver cirrhosis non-invasively through routine laboratory parameters? Infez Med 2014;22:11-18
-
(2014)
Infez Med
, vol.22
, pp. 11-18
-
-
Gentile, I.1
Buonomo, A.R.2
Zappulo, E.3
-
20
-
-
20044375378
-
The importance of HCV on the burden of chronic liver disease in Italy: A multicenter prevalence study of 9,997 cases
-
Sagnelli E, Stroffolini T, Mele A, et al. The importance of HCV on the burden of chronic liver disease in Italy: A multicenter prevalence study of 9,997 cases. J Med Virol 2005;75:522-7
-
(2005)
J Med Virol
, vol.75
, pp. 522-527
-
-
Sagnelli, E.1
Stroffolini, T.2
Mele, A.3
-
21
-
-
84878020247
-
Age and gender distribution of hepatitis C virus genotypes in the metropolitan area of Naples
-
Petruzziello A, Coppola N, Diodato AM, et al. Age and gender distribution of hepatitis C virus genotypes in the metropolitan area of Naples. Intervirology 2013;56:206-12
-
(2013)
Intervirology
, vol.56
, pp. 206-212
-
-
Petruzziello, A.1
Coppola, N.2
Diodato, A.M.3
-
22
-
-
84983122789
-
Hepatitis C virus infection in an endemic area of Southern Italy 14 years later: Evidence for a vanishing infection
-
Guadagnino V, Stroffolini T, Caroleo B, et al. Hepatitis C virus infection in an endemic area of Southern Italy 14 years later: Evidence for a vanishing infection. Dig Liver Dis 2013;45:403-7
-
(2013)
Dig Liver Dis
, vol.45
, pp. 403-407
-
-
Guadagnino, V.1
Stroffolini, T.2
Caroleo, B.3
-
23
-
-
12644279860
-
Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: A community-based survey in southern Italy
-
Guadagnino V, Stroffolini T, Rapicetta M, et al. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: A community-based survey in southern Italy. Hepatology 1997;26:1006-11
-
(1997)
Hepatology
, vol.26
, pp. 1006-1011
-
-
Guadagnino, V.1
Stroffolini, T.2
Rapicetta, M.3
-
24
-
-
84878750736
-
Acute hepatitis C in patients undergoing hemodialysis: Experience with high-dose interferon therapy
-
Gentile I, Di Flumeri G, Scarica S, et al. Acute hepatitis C in patients undergoing hemodialysis: Experience with high-dose interferon therapy. Minerva Urol Nefrol 2013;65:83-4
-
(2013)
Minerva Urol Nefrol
, vol.65
, pp. 83-84
-
-
Gentile, I.1
Di Flumeri, G.2
Scarica, S.3
-
25
-
-
84879126730
-
Association of tattooing and hepatitis C virus infection: A multicenter case-control study
-
Carney K, Dhalla S, Aytaman A, et al. Association of tattooing and hepatitis C virus infection: A multicenter case-control study. Hepatology 2013;57:2117-23
-
(2013)
Hepatology
, vol.57
, pp. 2117-2123
-
-
Carney, K.1
Dhalla, S.2
Aytaman, A.3
-
26
-
-
72049112561
-
Improvement in the aetiological diagnosis of acute hepatitis C: A diagnostic protocol based on the anti-HCV-IgM titre and IgG Avidity Index
-
Coppola N, Pisapia R, Tonziello G, et al. Improvement in the aetiological diagnosis of acute hepatitis C: A diagnostic protocol based on the anti-HCV-IgM titre and IgG Avidity Index. J Clin Virol 2009;46:222-9
-
(2009)
J Clin Virol
, vol.46
, pp. 222-229
-
-
Coppola, N.1
Pisapia, R.2
Tonziello, G.3
-
27
-
-
34548693175
-
Anti-HCV IgG avidity index in acute hepatitis C
-
Coppola N, Pisapia R, Marrocco C, et al. Anti-HCV IgG avidity index in acute hepatitis C. J Clin Virol 2007;40:110-15
-
(2007)
J Clin Virol
, vol.40
, pp. 110-115
-
-
Coppola, N.1
Pisapia, R.2
Marrocco, C.3
-
28
-
-
84881451656
-
Concomitant interferon-Alpha and chemotherapy in hepatitis C and colorectal cancer: A case report
-
Gentile I, De Stefano A, Di Flumeri G, et al. Concomitant interferon-Alpha and chemotherapy in hepatitis C and colorectal cancer: A case report. In Vivo 2013;27:527-9
-
(2013)
Vivo
, vol.27
, pp. 527-529
-
-
Gentile, I.1
De Stefano, A.2
Di Flumeri, G.3
-
29
-
-
75149163334
-
Aging of hepatitis C virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression
-
Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010;138:513-21
-
(2010)
Gastroenterology
, vol.138
, pp. 513-521
-
-
Davis, G.L.1
Alter, M.J.2
El-Serag, H.3
-
30
-
-
67651174428
-
A simple noninvasive score predicts gastroesophageal varices in patients with chronic viral hepatitis
-
Gentile I, Viola C, Graf M, et al. A simple noninvasive score predicts gastroesophageal varices in patients with chronic viral hepatitis. J Clin Gastroenterol 2009;43:81-7
-
(2009)
J Clin Gastroenterol
, vol.43
, pp. 81-87
-
-
Gentile, I.1
Viola, C.2
Graf, M.3
-
31
-
-
77951648047
-
Surrogate endpoints and non-inferiority trials in chronic viral hepatitis
-
Gentile I, Borgia G. Surrogate endpoints and non-inferiority trials in chronic viral hepatitis. J Hepatol 2010;52:778
-
(2010)
J Hepatol
, vol.52
, pp. 778
-
-
Gentile, I.1
Borgia, G.2
-
32
-
-
35648970573
-
Effect of sustained virological response on long-Term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin
-
Braks RE, Ganne-Carrie N, Fontaine H, et al. Effect of sustained virological response on long-Term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol 2007;13:5648-53
-
(2007)
World J Gastroenterol
, vol.13
, pp. 5648-5653
-
-
Braks, R.E.1
Ganne-Carrie, N.2
Fontaine, H.3
-
33
-
-
4644224871
-
Long-Term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy
-
Tsuda N, Yuki N, Mochizuki K, et al. Long-Term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy. J Med Virol 2004;74:406-13
-
(2004)
J Med Virol
, vol.74
, pp. 406-413
-
-
Tsuda, N.1
Yuki, N.2
Mochizuki, K.3
-
34
-
-
33947360829
-
Sustained virological response to interferon-Alpha is associated with improved outcome in HCV-related cirrhosis: A retrospective study
-
Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-Alpha is associated with improved outcome in HCV-related cirrhosis: A retrospective study. Hepatology 2007;45:579-87
-
(2007)
Hepatology
, vol.45
, pp. 579-587
-
-
Bruno, S.1
Stroffolini, T.2
Colombo, M.3
-
35
-
-
34548227085
-
Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: A randomized controlled trial
-
Di Marco V, Almasio PL, Ferraro D, et al. Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: A randomized controlled trial. J Hepatol 2007;47:484-91
-
(2007)
J Hepatol
, vol.47
, pp. 484-491
-
-
Di Marco, V.1
Almasio, P.L.2
Ferraro, D.3
-
36
-
-
0037063113
-
Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection
-
Hermine O, Lefrere F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002;347:89-94
-
(2002)
N Engl J Med
, vol.347
, pp. 89-94
-
-
Hermine, O.1
Lefrere, F.2
Bronowicki, J.P.3
-
37
-
-
84867802123
-
Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection
-
Takahashi K, Nishida N, Kawabata H, et al. Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection. Intern Med 2012;51:2745-7
-
(2012)
Intern Med
, vol.51
, pp. 2745-2747
-
-
Takahashi, K.1
Nishida, N.2
Kawabata, H.3
-
38
-
-
84877795646
-
Sustained virological response: A milestone in the treatment of chronic hepatitis C
-
Morisco F, Granata R, Stroffolini T, et al. Sustained virological response: A milestone in the treatment of chronic hepatitis C. World J Gastroenterol 2013;19:2793-8
-
(2013)
World J Gastroenterol
, vol.19
, pp. 2793-2798
-
-
Morisco, F.1
Granata, R.2
Stroffolini, T.3
-
39
-
-
84877782905
-
Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies
-
Chen J, Florian J, Carter W, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013;144:1450-5
-
(2013)
Gastroenterology
, vol.144
, pp. 1450-1455
-
-
Chen, J.1
Florian, J.2
Carter, W.3
-
40
-
-
79954669573
-
Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-Alfa based therapy
-
Lange CM, Bojunga J, Ramos-Lopez E, et al. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-Alfa based therapy. J Hepatol 2011;54:887-93
-
(2011)
J Hepatol
, vol.54
, pp. 887-893
-
-
Lange, C.M.1
Bojunga, J.2
Ramos-Lopez, E.3
-
41
-
-
84896126011
-
Prediction of sustained virologic responses to combination therapy of pegylated interferon-Alpha and ribavirin in patients with chronic hepatitis C infection
-
Ismail MH. Prediction of sustained virologic responses to combination therapy of pegylated interferon-Alpha and ribavirin in patients with chronic hepatitis C infection. J Fam Community Med 2013;20:35-40
-
(2013)
J Fam Community Med
, vol.20
, pp. 35-40
-
-
Ismail, M.H.1
-
42
-
-
58149484038
-
Homocysteine levels and sustained virological response to pegylatedinterferon alpha2b plus ribavirin therapy for chronic hepatitis C: A prospective study
-
Borgia G, Gentile I, Fortunato G, et al. Homocysteine levels and sustained virological response to pegylatedinterferon alpha2b plus ribavirin therapy for chronic hepatitis C: A prospective study. Liver Int 2009;29:248-52
-
(2009)
Liver Int
, vol.29
, pp. 248-252
-
-
Borgia, G.1
Gentile, I.2
Fortunato, G.3
-
43
-
-
0035990966
-
Raised serum ferritin predicts nonresponse to interferon and ribavirin treatment in patients with chronic hepatitis C infection
-
Distante S, Bjoro K, Hellum KB, et al. Raised serum ferritin predicts nonresponse to interferon and ribavirin treatment in patients with chronic hepatitis C infection. Liver 2002;22:269-75
-
(2002)
Liver
, vol.22
, pp. 269-275
-
-
Distante, S.1
Bjoro, K.2
Hellum, K.B.3
-
44
-
-
70449601851
-
Iron depletion before HCV antiviral therapy: A pilot, randomized, controlled trial
-
Gentile I, Viola C, Paesano L, et al. Iron depletion before HCV antiviral therapy: A pilot, randomized, controlled trial. J Clin Apher 2009;24:190-6
-
(2009)
J Clin Apher
, vol.24
, pp. 190-196
-
-
Gentile, I.1
Viola, C.2
Paesano, L.3
-
45
-
-
83755196636
-
Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naive patients
-
Abu-Mouch S, Fireman Z, Jarchovsky J, et al. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naive patients. World J Gastroenterol 2011;17:5184-90
-
(2011)
World J Gastroenterol
, vol.17
, pp. 5184-5190
-
-
Abu-Mouch, S.1
Fireman, Z.2
Jarchovsky, J.3
-
46
-
-
84857532001
-
Vitamin D improves viral response in hepatitis C genotype 2-3 naive patients
-
Nimer A, Mouch A. Vitamin D improves viral response in hepatitis C genotype 2-3 naive patients. World J Gastroenterol 2012;18:800-5
-
(2012)
World J Gastroenterol
, vol.18
, pp. 800-805
-
-
Nimer, A.1
Mouch, A.2
-
47
-
-
84896959418
-
Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection
-
Coppola N, Marrone A, Pisaturo M, et al. Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection. Eur J Clin Microbiol Infect Dis 2014;33:559-67
-
(2014)
Eur J Clin Microbiol Infect Dis
, vol.33
, pp. 559-567
-
-
Coppola, N.1
Marrone, A.2
Pisaturo, M.3
-
48
-
-
33749241866
-
Discovery of (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[ 1,1-dimethylethyl)amino] carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6- dimethyl-3-Azabicyclo [3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: A potential therapeutic agent for the treatment of hepatitis C infection
-
Venkatraman S, Bogen SL, Arasappan A, et al. Discovery of (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1, 1-dimethylethyl)amino] carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3- Azabicyclo [3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: A potential therapeutic agent for the treatment of hepatitis C infection. J Med Chem 2006;49:6074-86
-
(2006)
J Med Chem
, vol.49
, pp. 6074-6086
-
-
Venkatraman, S.1
Bogen, S.L.2
Arasappan, A.3
-
49
-
-
33646036163
-
Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034
-
Tong X, Chase R, Skelton A, et al. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 2006;70:28-38
-
(2006)
Antiviral Res
, vol.70
, pp. 28-38
-
-
Tong, X.1
Chase, R.2
Skelton, A.3
-
50
-
-
33744457959
-
Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease
-
Lin C, Kwong AD, Perni RB. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets 2006;6:3-16
-
(2006)
Infect Disord Drug Targets
, vol.6
, pp. 3-16
-
-
Lin, C.1
Kwong, A.D.2
Perni, R.B.3
-
51
-
-
65649142019
-
Telaprevir: A promising protease inhibitor for the treatment of hepatitis C virus infection
-
Gentile I, Viola C, Borgia F, et al. Telaprevir: A promising protease inhibitor for the treatment of hepatitis C virus infection. Curr Med Chem 2009;16:1115-21
-
(2009)
Curr Med Chem
, vol.16
, pp. 1115-1121
-
-
Gentile, I.1
Viola, C.2
Borgia, F.3
-
52
-
-
84871109075
-
Efficacy of Pegylated interferon alpha-2a and alpha-2b in patients with genotype 1 chronic hepatitis C: A meta-Analysis
-
Coppola N, Pisaturo M, Tonziello G, et al. Efficacy of Pegylated interferon alpha-2a and alpha-2b in patients with genotype 1 chronic hepatitis C: A meta-Analysis. BMC Infect Dis 2012;12:1471-2334
-
(2012)
BMC Infect Dis
, vol.12
, pp. 1471-2334
-
-
Coppola, N.1
Pisaturo, M.2
Tonziello, G.3
-
53
-
-
65449136656
-
Diagnosis, management, and treatment of hepatitis C: An update
-
Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 2009;49:1335-74
-
(2009)
Hepatology
, vol.49
, pp. 1335-1374
-
-
Ghany, M.G.1
Strader, D.B.2
Thomas, D.L.3
-
56
-
-
84877739274
-
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options
-
Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867-77
-
(2013)
N Engl J Med
, vol.368
, pp. 1867-1877
-
-
Jacobson, I.M.1
Gordon, S.C.2
Kowdley, K.V.3
-
57
-
-
84877730954
-
Sofosbuvir for previously untreated chronic hepatitis C infection
-
Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-87
-
(2013)
N Engl J Med
, vol.368
, pp. 1878-1887
-
-
Lawitz, E.1
Mangia, A.2
Wyles, D.3
-
58
-
-
84896134666
-
Efficacy and safety of sofosbuvir in treatment of chronic hepatitis C: The dawn of the a new era
-
In press
-
Gentile I, Borgia F, Zappulo E, et al. Efficacy and safety of sofosbuvir in treatment of chronic hepatitis C: The dawn of the a new era. Rev Recent Clin Trials 2013; In press
-
(2013)
Rev Recent Clin Trials
-
-
Gentile, I.1
Borgia, F.2
Zappulo, E.3
-
59
-
-
84892751187
-
Sofosbuvir + Ribavirin for 12 or 24 Weeks for Patients with HCV Genotype 2 or 3: The VALENCE trial
-
Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir + Ribavirin for 12 or 24 Weeks for Patients with HCV Genotype 2 or 3: The VALENCE trial. Hepatology 2013;58:733-4
-
(2013)
Hepatology
, vol.58
, pp. 733-734
-
-
Zeuzem, S.1
Dusheiko, G.M.2
Salupere, R.3
-
60
-
-
80053339008
-
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases
-
Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:1433-44
-
(2011)
Hepatology
, vol.54
, pp. 1433-1444
-
-
Ghany, M.G.1
Nelson, D.R.2
Strader, D.B.3
-
61
-
-
84883404339
-
A novel promising therapeutic option against hepatitis C virus: An oral nucleotide NS5B polymerase inhibitor sofosbuvir
-
Gentile I, Borgia F, Buonomo AR, et al. A novel promising therapeutic option against hepatitis C virus: An oral nucleotide NS5B polymerase inhibitor sofosbuvir. Curr Med Chem 2013;20:3733-42
-
(2013)
Curr Med Chem
, vol.20
, pp. 3733-3742
-
-
Gentile, I.1
Borgia, F.2
Buonomo, A.R.3
-
62
-
-
84856410313
-
Antiviral strategies in hepatitis C virus infection
-
Sarrazin C, Hezode C, Zeuzem S, et al. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012;56:S88-S100
-
(2012)
J Hepatol
, vol.56
-
-
Sarrazin, C.1
Hezode, C.2
Zeuzem, S.3
-
63
-
-
84898439254
-
Daclatasvir: The first of a new class of drugs targeted against hepatitis C virus NS5A
-
Gentile I, Borgia F, Coppola N, et al. Daclatasvir: The first of a new class of drugs targeted against hepatitis C virus NS5A. Curr Med Chem 2014;21:1391-404
-
(2014)
Curr Med Chem
, vol.21
, pp. 1391-1404
-
-
Gentile, I.1
Borgia, F.2
Coppola, N.3
-
64
-
-
84874107832
-
Perspectives and challenges of interferon-free therapy for chronic hepatitis C
-
Lange CM, Zeuzem S. Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol 2013;58:583-92
-
(2013)
J Hepatol
, vol.58
, pp. 583-592
-
-
Lange, C.M.1
Zeuzem, S.2
-
65
-
-
84896138890
-
Ledipasvir : A novel synthetic antiviral for the treatment of HCV infection
-
Gentile I, Buonomo AR, Borgia F, et al. Ledipasvir : A novel synthetic antiviral for the treatment of HCV infection. Expert Opin Investig Drugs 2014;23:561-71
-
(2014)
Expert Opin Investig Drugs
, vol.23
, pp. 561-571
-
-
Gentile, I.1
Buonomo, A.R.2
Borgia, F.3
-
66
-
-
23944476834
-
Unravelling hepatitis C virus replication from genome to function
-
Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature 2005;436:933-8
-
(2005)
Nature
, vol.436
, pp. 933-938
-
-
Lindenbach, B.D.1
Rice, C.M.2
-
67
-
-
36248994744
-
Specifically targeted antiviral therapy for hepatitis C virus
-
Parfieniuk A, Jaroszewicz J, Flisiak R. Specifically targeted antiviral therapy for hepatitis C virus. World J Gastroenterol 2007;13(43):5673-81
-
(2007)
World J Gastroenterol
, vol.13
, Issue.43
, pp. 5673-5681
-
-
Parfieniuk, A.1
Jaroszewicz, J.2
Flisiak, R.3
-
68
-
-
72049091527
-
The efficacy and safety of telaprevir-A new protease inhibitor against hepatitis C virus
-
Gentile I, Carleo MA, Borgia F, et al. The efficacy and safety of telaprevir-A new protease inhibitor against hepatitis C virus. Expert Opin Investig Drugs 2010;19:151-9
-
(2010)
Expert Opin Investig Drugs
, vol.19
, pp. 151-159
-
-
Gentile, I.1
Carleo, M.A.2
Borgia, F.3
-
69
-
-
84906057792
-
Different incorporation efficiencies for nucleotide analogs during HCV polymerase RNA synthesis initiation and elongation phases
-
Ma H, Inocencio N, Leveque V, et al. Different incorporation efficiencies for nucleotide analogs during HCV polymerase RNA synthesis initiation and elongation phases. Antiviral Res 2008;78:A22-3
-
(2008)
Antiviral Res
, vol.78
-
-
Ma, H.1
Inocencio, N.2
Leveque, V.3
-
71
-
-
84898441875
-
MK-5172 : A second-generation protease inhibitor for the treatment of hepatitis C virus infection
-
Gentile I, Buonomo AR, Borgia F, et al. MK-5172 : A second-generation protease inhibitor for the treatment of hepatitis C virus infection. Expert Opin Investig Drugs 2014;23:719-28
-
(2014)
Expert Opin Investig Drugs
, vol.23
, pp. 719-728
-
-
Gentile, I.1
Buonomo, A.R.2
Borgia, F.3
-
73
-
-
84880659527
-
All-oral HCV therapies near approval
-
Tse MT. All-oral HCV therapies near approval. Nat Rev Drug Discov 2013;12(6):409-11
-
(2013)
Nat Rev Drug Discov
, vol.12
, Issue.6
, pp. 409-411
-
-
Tse, M.T.1
-
75
-
-
84890947330
-
Novel therapeutic approaches for hepatitis C
-
Au JS, Pockros PJ. Novel therapeutic approaches for hepatitis C. Clin Pharmacol Ther 2014;95:78-88
-
(2014)
Clin Pharmacol Ther
, vol.95
, pp. 78-88
-
-
Au, J.S.1
Pockros, P.J.2
-
76
-
-
33646457538
-
Inhibition of hepatitis C replicon RNA synthesis by beta-D-2-deoxy-2- fluoro-2-C-methylcytidine: A specific inhibitor of hepatitis C virus replication
-
Stuyver LJ, McBrayer TR, Tharnish PM, et al. Inhibition of hepatitis C replicon RNA synthesis by beta-D-2-deoxy-2-fluoro-2-C-methylcytidine: A specific inhibitor of hepatitis C virus replication. Antivir Chem Chemother 2006;17:79-87
-
(2006)
Antivir Chem Chemother
, vol.17
, pp. 79-87
-
-
Stuyver, L.J.1
McBrayer, T.R.2
Tharnish, P.M.3
-
77
-
-
84906063038
-
Single-dose pharmacokinetics of the HCV polymerase inhibitor Mericitabine in Healthy Caucasian and Japanese Subjects
-
Washington C, Moreira S, Haznedar J, et al. Single-dose pharmacokinetics of the HCV polymerase inhibitor Mericitabine in Healthy Caucasian and Japanese Subjects. Drug Metab Pharmacokinet 2013;10:10
-
(2013)
Drug Metab Pharmacokinet
, vol.10
, pp. 10
-
-
Washington, C.1
Moreira, S.2
Haznedar, J.3
-
78
-
-
84885318167
-
The effect of mild to moderate renal impairment on the pharmacokinetics (PK of the hepatitis c virus (HCV) polymerase inhibitor mericitabine (MCB, RG7128)
-
Moreira S, Haznedar J, Marbury TC, et al. The effect of mild to moderate renal impairment on the pharmacokinetics (PK) of the hepatitis c virus (HCV) polymerase inhibitor mericitabine (MCB, RG7128). Hepatology 2011;54:537A-8A
-
(2011)
Hepatology
, vol.54
-
-
Moreira, S.1
Haznedar, J.2
Marbury, T.C.3
-
79
-
-
84906054487
-
No impact of cirrhosis on mericitabine (MCB pharmacokinetics and early antiviral activity in hepatitis C-infected patients receiving MCB plus peginterferon alfa-2a (40KD)/ribavirin (P/R)
-
Moreira S, Levi M, Kulkarni R, et al. No impact of cirrhosis on mericitabine (MCB) pharmacokinetics and early antiviral activity in hepatitis C-infected patients receiving MCB plus peginterferon alfa-2a (40KD)/ribavirin (P/R). Hepatology 2012;56:583A-A
-
(2012)
Hepatology
, vol.56
-
-
Moreira, S.1
Levi, M.2
Kulkarni, R.3
-
80
-
-
41349083638
-
Antiviral activity, pharmacokinetics, safety and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy
-
Reddy R, Rodriguez-Torres M, Gane E, et al. Antiviral activity, pharmacokinetics, safety and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy. Hepatology 2007;46:862A-3A
-
(2007)
Hepatology
, vol.46
-
-
Reddy, R.1
Rodriguez-Torres, M.2
Gane, E.3
-
81
-
-
46249112617
-
Potent antiviral activity of the HCV nucleoside polymerase inhibitor R7128 with Peg-IFN and ribavirin: Interim results of R7128 500mg BID for 28 days
-
Lalezari J, Gane E, Rodriguez-Torres M, et al. Potent antiviral activity of the HCV nucleoside polymerase inhibitor R7128 with Peg-IFN and ribavirin: Interim results of R7128 500mg BID for 28 days. J Hepatol 2008;48:S29
-
(2008)
J Hepatol
, vol.48
-
-
Lalezari, J.1
Gane, E.2
Rodriguez-Torres, M.3
-
82
-
-
84863396230
-
Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128
-
Guedj J, Dahari H, Shudo E, et al. Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). Hepatology 2012;55:1030-7
-
(2012)
Hepatology
, vol.55
, pp. 1030-1037
-
-
Guedj, J.1
Dahari, H.2
Shudo, E.3
-
83
-
-
59149098021
-
Antiviral activity of the HCV nucleoside polymerase inhibitor R7128 in HCV genotype 2 and 3 prior non-responders: Interim results of R7128 1500mg bid with PEG-IFN and ribavirin for 28 days
-
Gane EJ, Rodriguez-Torres M, Nelson DR, et al. Antiviral activity of the HCV nucleoside polymerase inhibitor R7128 in HCV genotype 2 and 3 prior non-responders: Interim results of R7128 1500mg bid with PEG-IFN and ribavirin for 28 days. Hepatology 2008;48:1024A-A
-
(2008)
Hepatology
, vol.48
-
-
Gane, E.J.1
Rodriguez-Torres, M.2
Nelson, D.R.3
-
84
-
-
77958162291
-
Sustained virologic response (SVR) following RG7128 1500mg bid/PEG-IFN/RBV for 28 days in HCV genotype 2/3 prior non-responders
-
Gane EJ, Rodriguez-Torres M, Nelson DE, et al. Sustained virologic response (SVR) following RG7128 1500mg bid/PEG-IFN/RBV for 28 days in HCV genotype 2/3 prior non-responders. J Hepatol 2010;52:S16
-
(2010)
J Hepatol
, vol.52
-
-
Gane, E.J.1
Rodriguez-Torres, M.2
Nelson, D.E.3
-
85
-
-
84879211393
-
PROPEL: A randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naive HCV genotype 1/4 patients
-
Wedemeyer H, Jensen D, Herring R Jr, et al. PROPEL: A randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naive HCV genotype 1/4 patients. Hepatology 2013;58:524-37
-
(2013)
Hepatology
, vol.58
, pp. 524-537
-
-
Wedemeyer, H.1
Jensen, D.2
Herring Jr., R.3
-
86
-
-
84881025292
-
JUMP-C: A randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naive HCV genotype 1/4 patients
-
Pockros PJ, Jensen D, Tsai N, et al. JUMP-C: A randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naive HCV genotype 1/4 patients. Hepatology 2013;58:514-23
-
(2013)
Hepatology
, vol.58
, pp. 514-523
-
-
Pockros, P.J.1
Jensen, D.2
Tsai, N.3
-
87
-
-
84894271490
-
In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir
-
Tong X, Le Pogam S, Li L, et al. In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir. J Infect Dis 2014;209:668-75
-
(2014)
J Infect Dis
, vol.209
, pp. 668-675
-
-
Tong, X.1
Le Pogam, S.2
Li, L.3
-
88
-
-
78049527728
-
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): A randomised, doubleblind, placebo-controlled, dose-escalation trial
-
Gane EJ, Roberts SK, Stedman CAM, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): A randomised, doubleblind, placebo-controlled, dose-escalation trial. Lancet 2010;376:1467-75
-
(2010)
Lancet
, vol.376
, pp. 1467-1475
-
-
Gane, E.J.1
Roberts, S.K.2
Stedman, C.A.M.3
-
89
-
-
84868029979
-
Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short-Term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir
-
Le Pogam S, Yan JM, Chhabra M, et al. Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short-Term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir. Antimicrob Agents Chemother 2012;56:5494-502
-
(2012)
Antimicrob Agents Chemother
, vol.56
, pp. 5494-5502
-
-
Le Pogam, S.1
Yan, J.M.2
Chhabra, M.3
-
90
-
-
78349268362
-
RG7128 alone or in combination with pegylated interferon-Alpha2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients
-
Le Pogam S, Seshaadri A, Ewing A, et al. RG7128 alone or in combination with pegylated interferon-Alpha2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients. J Infect Dis 2010;202:1510-19
-
(2010)
J Infect Dis
, vol.202
, pp. 1510-1519
-
-
Le Pogam, S.1
Seshaadri, A.2
Ewing, A.3
-
91
-
-
84878136958
-
Up to 100% SVR4 rates with ritonavirboosted danoprevir (DNVr), mericitabine (MCB) and ribavirin (R) +/-peginterferon alfa-2a (40KD) (P) in HCV genotype 1-infected partial and null responders: Results from the MATTERHORN study
-
Feld JJ, Jacobson IM, Jensen DM, et al. Up to 100% SVR4 rates with ritonavirboosted danoprevir (DNVr), mericitabine (MCB) and ribavirin (R) +/-peginterferon alfa-2a (40KD) (P) in HCV genotype 1-infected partial and null responders: Results from the MATTERHORN study. Hepatology 2012;56:231A-2A
-
(2012)
Hepatology
, vol.56
-
-
Feld, J.J.1
Jacobson, I.M.2
Jensen, D.M.3
-
92
-
-
84906064180
-
Interferon-free regimen containing setrobuvir (STV) in combination with ritonavir-boosted danoprevir (DNVr) and ribavirin (R) with or without mericitabine (MCB) in HCV genotype (G)1 treatment-naive patients: Interim SVR4 results from the ANNAPURNA study
-
Jensen DM, Brunda M, Elston R, et al. Interferon-free regimen containing setrobuvir (STV) in combination with ritonavir-boosted danoprevir (DNVr) and ribavirin (R) with or without mericitabine (MCB) in HCV genotype (G)1 treatment-naive patients: Interim SVR4 results from the ANNAPURNA study. Hepatology 2013;58:741A
-
(2013)
Hepatology
, vol.58
-
-
Jensen, D.M.1
Brunda, M.2
Elston, R.3
-
93
-
-
84884304405
-
Meeting report: 26th International Conference on Antiviral Research
-
Vere Hodge RA. Meeting report: 26th International Conference on Antiviral Research. Antiviral Res 2013;100:276-85
-
(2013)
Antiviral Res
, vol.100
, pp. 276-285
-
-
Vere Hodge, R.A.1
-
94
-
-
84906053170
-
Preclinical characterization of ALS-2200, a potent nucleotide polymerase inhibitor for the treatment of chronic hepatitis C
-
Tan H, Deval J, Kang H, et al. Preclinical characterization of ALS-2200, a potent nucleotide polymerase inhibitor for the treatment of chronic hepatitis C. Hepatology 2012;56:1069A-70A
-
(2012)
Hepatology
, vol.56
-
-
Tan, H.1
Deval, J.2
Kang, H.3
-
95
-
-
84906056707
-
In vitro resistance to ALS-2200, a potent nucleotide polymerase inhibitor for the treatment of chronic hepatitis C
-
Tan H, Jekle A, Kang H, et al. In vitro resistance to ALS-2200, a potent nucleotide polymerase inhibitor for the treatment of chronic hepatitis C. J Hepatol 2013;58:S496
-
(2013)
J Hepatol
, vol.58
-
-
Tan, H.1
Jekle, A.2
Kang, H.3
-
96
-
-
84898609302
-
Analysis of ALS-2200, a novel potent nucleotide analog, combination drug interactions in the hepatitis C virus (HCV) subgenomic replicon system
-
Tan H, Kang H, Moy C, et al. Analysis of ALS-2200, a novel potent nucleotide analog, combination drug interactions in the hepatitis C virus (HCV) subgenomic replicon system. Hepatology 2012;56:1072A-A
-
(2012)
Hepatology
, vol.56
-
-
Tan, H.1
Kang, H.2
Moy, C.3
-
97
-
-
84872037558
-
ALS-2200, a novel once-daily nucleotide HCV polymerase inhibitor, demonstrates potent antiviral activity over 7 days in treatment-naive genotype 1 (GT1) patients
-
Marcellin P, Popa S, Berliba A, et al. ALS-2200, a novel once-daily nucleotide HCV polymerase inhibitor, demonstrates potent antiviral activity over 7 days in treatment-naive genotype 1 (GT1) patients. Hepatology 2012;56:235A-A
-
(2012)
Hepatology
, vol.56
-
-
Marcellin, P.1
Popa, S.2
Berliba, A.3
-
98
-
-
84906058337
-
ALS-2200, a novel once-daily nucleotide HCV polymerase inhibitor, demonstrated potent antiviral activity in treatment-naive patients with compensated cirrhosis or genotype 2-4 chronic hepatitis C
-
Marcellin P, Popa S, Streinu-Cercel A, et al. ALS-2200, a novel once-daily nucleotide HCV polymerase inhibitor, demonstrated potent antiviral activity in treatment-naive patients with compensated cirrhosis or genotype 2-4 chronic hepatitis C. J Hepatol 2013;58:S355
-
(2013)
J Hepatol
, vol.58
-
-
Marcellin, P.1
Popa, S.2
Streinu-Cercel, A.3
-
99
-
-
84906046362
-
VX-135, a potent single diastereomer of ALS-2200, for the treatment of chronic hepatitis C
-
Tan H, Deval J, Kang H, et al. VX-135, a potent single diastereomer of ALS-2200, for the treatment of chronic hepatitis C. J Hepatol 2013;58:S495
-
(2013)
J Hepatol
, vol.58
-
-
Tan, H.1
Deval, J.2
Kang, H.3
-
100
-
-
84906054914
-
VX-135, a once-daily nucleotide HCV polymerase inhibitor, was well tolerated and demonstrated potent antiviral activity when given with ribavirin in treatment-naïve patients with genotype 1 HCV
-
Popa S, Berliba A, Ghicavii N, et al. VX-135, a once-daily nucleotide HCV polymerase inhibitor, was well tolerated and demonstrated potent antiviral activity when given with ribavirin in treatment-naïve patients with genotype 1 HCV. Hepatology 2013;58:745A
-
(2013)
Hepatology
, vol.58
-
-
Popa, S.1
Berliba, A.2
Ghicavii, N.3
-
101
-
-
77955426384
-
Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus
-
McGuigan C, Madela K, Aljarah M, et al. Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus. Bioorg Med Chem Lett 2010;20:4850-4
-
(2010)
Bioorg Med Chem Lett
, vol.20
, pp. 4850-4854
-
-
McGuigan, C.1
Madela, K.2
Aljarah, M.3
-
102
-
-
79955529751
-
INX-08189, a phosphoramidate prodrug of 6-O-methyl-2-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties
-
Vernachio JH, Bleiman B, Bryant KD, et al. INX-08189, a phosphoramidate prodrug of 6-O-methyl-2-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties. Antimicrob Agents Chemother 2011;55:1843-51
-
(2011)
Antimicrob Agents Chemother
, vol.55
, pp. 1843-1851
-
-
Vernachio, J.H.1
Bleiman, B.2
Bryant, K.D.3
-
103
-
-
84906066665
-
In vitro characterization of the combination of daclatasvir, an NS5A inhibitor, and BMS-986094 (INX-08189), a precursor to an NS5B inhibitor
-
Li W, Gao M, Hall A, et al. In vitro characterization of the combination of daclatasvir, an NS5A inhibitor, and BMS-986094 (INX-08189), a precursor to an NS5B inhibitor. Hepatology 2012;56:1074A-5A
-
(2012)
Hepatology
, vol.56
-
-
Li, W.1
Gao, M.2
Hall, A.3
-
104
-
-
84892854326
-
A study of the safety and pharmacokinetics of single ascending oral doses of INX-08189, a nucleotide polymerase inhibitor, in healthy subjects
-
Patti J, Matson M, Boehlecke B, et al. A study of the safety and pharmacokinetics of single ascending oral doses of INX-08189, a nucleotide polymerase inhibitor, in healthy subjects. J Hepatol 2011;54:S187
-
(2011)
J Hepatol
, vol.54
-
-
Patti, J.1
Matson, M.2
Boehlecke, B.3
-
105
-
-
84906047769
-
Evaluation of potential pharmacokinetic drug-drug interaction between BMS-986094 (INX-08189) and verapamil when coadministered in healthy subjects
-
Campaneria R, Barry AN, Patti J, et al. Evaluation of potential pharmacokinetic drug-drug interaction between BMS-986094 (INX-08189) and verapamil when coadministered in healthy subjects. Hepatology 2012;56:1074A-A
-
(2012)
Hepatology
, vol.56
-
-
Campaneria, R.1
Barry, A.N.2
Patti, J.3
-
106
-
-
84890312082
-
Antiviral activity and safety of INX-08189, a nucleotide polymerase inhibitor, following 7-days of oral therapy in naive genotype-1 chronic HCV patients
-
Rodriguez-Torres M, Lawitz E, Hazan L, et al. Antiviral activity and safety of INX-08189, a nucleotide polymerase inhibitor, following 7-days of oral therapy in naive genotype-1 chronic HCV patients. Hepatology 2011;54:535A-A
-
(2011)
Hepatology
, vol.54
-
-
Rodriguez-Torres, M.1
Lawitz, E.2
Hazan, L.3
-
107
-
-
84892856547
-
BMS-986094 (INX-08189) plus peginterferon alfa-2a and ribavirin results in increased rates of rapid virologic response (RVR) and eRVR in treatment-naive HCV-genotype 2/3 patients compared to peginterferon alfa-2a and ribavirin: Week 12 results
-
Lawitz E, Lalezari J, Freilich B, et al. BMS-986094 (INX-08189) plus peginterferon alfa-2a and ribavirin results in increased rates of rapid virologic response (RVR) and eRVR in treatment-naive HCV-genotype 2/3 patients compared to peginterferon alfa-2a and ribavirin: Week 12 results. Hepatology 2012;56:566A-7A
-
(2012)
Hepatology
, vol.56
-
-
Lawitz, E.1
Lalezari, J.2
Freilich, B.3
-
108
-
-
84902940042
-
-
[Abstract MEDI 21 Abstracts of Papers of theftxt American Chemical Society 2012;244th National Meeting and Exposition
-
Cho A, Zhang L, Xu J, et al. Discovery of GS-6620: C-nucleoside HCV polymerase inhibitor [Abstract MEDI 21]. Abstracts of Papers of the American Chemical Society 2012;244th National Meeting and Exposition
-
Discovery of GS-6620: C-nucleoside HCV Polymerase Inhibitor
-
-
Cho, A.1
Zhang, L.2
Xu, J.3
-
109
-
-
84871152367
-
GS-6620: A liver targeted nucleotide prodrug with potent pan-genotype anti-hepatitis C virus activity in vitro
-
Ray AS, Feng JY, Wang T, et al. GS-6620: A liver targeted nucleotide prodrug with potent pan-genotype anti-hepatitis C virus activity in vitro. J Hepatol 2011;54:S487
-
(2011)
J Hepatol
, vol.54
-
-
Ray, A.S.1
Feng, J.Y.2
Wang, T.3
-
110
-
-
84879413512
-
GS-6620, a novel anti-hepatitis C virus nucleotide prodrug, has a high barrier to resistance in vitro
-
Fenaux M, Cheng G, Mabery E, et al. GS-6620, a novel anti-hepatitis C virus nucleotide prodrug, has a high barrier to resistance in vitro. J Hepatol 2011;54:S476
-
(2011)
J Hepatol
, vol.54
-
-
Fenaux, M.1
Cheng, G.2
Mabery, E.3
-
111
-
-
84873066836
-
Nucleotide inhibitor resistance selections using GT2A infectious virus: PSI-7851 and GS-6620 select for a novel resistance pathway including substitutions of M289V/L followed by S282T
-
Cheng G, Fenaux M, Mabery E, et al. Nucleotide inhibitor resistance selections using GT2A infectious virus: PSI-7851 and GS-6620 select for a novel resistance pathway including substitutions of M289V/L followed by S282T. J Hepatol 2011;54:S473
-
(2011)
J Hepatol
, vol.54
-
-
Cheng, G.1
Fenaux, M.2
Mabery, E.3
-
112
-
-
84906062823
-
Inhibition of hepatitis C virus replication by GS-6620, a potent c-nucleoside monophosphate prodrug
-
Feng JY, Cheng G, Perry J, et al. Inhibition of hepatitis C virus replication by GS-6620, a potent c-nucleoside monophosphate prodrug. Antimicrob Agents Chemother 2014;13:13
-
(2014)
Antimicrob Agents Chemother
, vol.13
, pp. 13
-
-
Feng, J.Y.1
Cheng, G.2
Perry, J.3
-
113
-
-
84870435875
-
GS-6620, a liver-Targeted nucleotide prodrug, exhibits antiviral activity and favorable safety profile over 5 days in treatment naive chronic HCV genotype 1 subjects
-
Lawitz E, Hill J, Marbury T, et al. GS-6620, a liver-Targeted nucleotide prodrug, exhibits antiviral activity and favorable safety profile over 5 days in treatment naive chronic HCV genotype 1 subjects. J Hepatol 2012;56:S470-S71
-
(2012)
J Hepatol
, vol.56
-
-
Lawitz, E.1
Hill, J.2
Marbury, T.3
-
114
-
-
84906057528
-
Metabolism and pharmacokinetics of the anti-HCV nucleotide prodrug GS-6620
-
Murakami E, Wang T, Babusis D, et al. Metabolism and pharmacokinetics of the anti-HCV nucleotide prodrug GS-6620. Antimicrob Agents Chemother 2014;13:13
-
(2014)
Antimicrob Agents Chemother
, vol.13
, pp. 13
-
-
Murakami, E.1
Wang, T.2
Babusis, D.3
-
115
-
-
84906057968
-
Preclinical characteristics of ACH-3422: A potent uridine nucleotide prodrug for inhibition of hepatitis C virus polymerase
-
Yang W, Wiles J, Patel D, et al. Preclinical characteristics of ACH-3422: A potent uridine nucleotide prodrug for inhibition of hepatitis C virus polymerase. Hepatology 2013;58:436A
-
(2013)
Hepatology
, vol.58
-
-
Yang, W.1
Wiles, J.2
Patel, D.3
-
116
-
-
84906060891
-
Discovery and preclinical profiling of LG-7501, a liver-Targeted hepatitis C virus (HCV) nucleotide NS5B polymerase inhibitor designed to improve clinical efficacy and safety
-
Vajda EG, Marschke KB, Henderson I, et al. Discovery and preclinical profiling of LG-7501, a liver-Targeted hepatitis C virus (HCV) nucleotide NS5B polymerase inhibitor designed to improve clinical efficacy and safety. Hepatology 2012;56:1080A-A
-
(2012)
Hepatology
, vol.56
-
-
Vajda, E.G.1
Marschke, K.B.2
Henderson, I.3
-
117
-
-
84906047032
-
HepDirect (TM) improves liver-Targeting of HCV nucleotide NS5B polymerase inhibitor LG-7501 versus phosphoramidate pronucleotide technology
-
Vajda EG, Marschke KB, Zhi L. HepDirect (TM) improves liver-Targeting of HCV nucleotide NS5B polymerase inhibitor LG-7501 versus phosphoramidate pronucleotide technology. J Hepatol 2013;58:S498-S99
-
(2013)
J Hepatol
, vol.58
-
-
Vajda, E.G.1
Marschke, K.B.2
Zhi, L.3
-
118
-
-
84906046479
-
Antiviral activity of EP-NI266, a potent nucleotide HCV polymerase inhibitor
-
Owens CM, Rhodin MHJ, Polemeropoulos A, et al. Antiviral activity of EP-NI266, a potent nucleotide HCV polymerase inhibitor. J Hepatol 2012;56:S475-S76
-
(2012)
J Hepatol
, vol.56
-
-
Owens, C.M.1
Rhodin, M.H.J.2
Polemeropoulos, A.3
-
119
-
-
84884127794
-
All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear
-
Lawitz EJ, Rodriguez-Torres M, Denning J, et al. All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear). J Viral Hepat 2013;20:699-707.
-
(2013)
J Viral Hepat
, vol.20
, pp. 699-707
-
-
Lawitz, E.J.1
Rodriguez-Torres, M.2
Denning, J.3
|